Cytosorbents/$CTSO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cytosorbents
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
- Ticker
- $CTSO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 129
- Headquarters
- Princeton, United States
- Website
- www.cytosorbents.com
Cytosorbents Metrics
BasicAdvanced
$17M
-
-$5.82
1.37
-
Price and volume
Market cap
$17M
Beta
1.37
52-week high
$7.44
52-week low
$2.84
Average daily volume
55K
Financial strength
Current ratio
0.655
Quick ratio
0.466
Long term debt to equity
-19.558
Total debt to equity
-39.182
Interest coverage (TTM)
-3.78%
Profitability
EBITDA (TTM)
-10.349
Gross margin (TTM)
71.61%
Net profit margin (TTM)
-48.94%
Operating margin (TTM)
-31.63%
Effective tax rate (TTM)
2.15%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-17.12%
Return on equity (TTM)
-336.21%
Valuation
Price to revenue (TTM)
0.45
Price to book
-22.34
Price to tangible book (TTM)
-4.64
Price to free cash flow (TTM)
-1.749
Free cash flow yield (TTM)
-57.17%
Free cash flow per share (TTM)
-3.053
Growth
Revenue change (TTM)
3.07%
Earnings per share change (TTM)
71.53%
3-year revenue growth (CAGR)
0.77%
10-year revenue growth (CAGR)
17.96%
3-year earnings per share growth (CAGR)
-21.65%
10-year earnings per share growth (CAGR)
-2.79%
Cytosorbents Financial Performance
Revenues and expenses
Cytosorbents Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.